Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13450969 | 0.85 | PIK3CA (0.44) | PTGS2PTGS1SCD | |
| SCHEMBL10119816 | 0.81 | GHSR (0.46) | PTGS2PTGS1GHSR | |
| SCHEMBL3151912 | 0.77 | PTGS2 (0.62) | PTGS2PTGS1HDAC6 | |
| SCHEMBL14002197 | 0.75 | PTGS1 (0.50) | PTGS2PTGS1 | |
| SCHEMBL3167177 | 0.74 | PTGS2 (0.43) | PTGS2PTGS1SCD | |
| SCHEMBL3166726 | 0.74 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL15257358 | 0.73 | PTGS2 (0.64) | PTGS2PTGS1PTGER1 | |
| SCHEMBL13451114 | 0.73 | PTGS2 (0.48) | PTGS2PTGS1HDAC6 | |
| SCHEMBL13666252 | 0.73 | GHSR (0.60) | PTGS2GHSR | |
| SCHEMBL13450400 | 0.72 | PTGS2 (0.52) | PTGS2PTGS1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546107-B1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7446117-B2 | Cox-2 inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-7446117-B2 | Cox-2 inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-7446117-B2 | Cox-2 inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| CN-1681788-A | COX-2 inhibiting pyridine derivatives | GLAXO GROUP LTD (GB) | 2005-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885GHSR 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.